Welcome to the HALAVEN® Nurse Hub for metastatic breast cancer (mBC)

At Eisai, we appreciate nurses and all that you do for your patients. Our HALAVEN Nurse Hub is a place where you can access videos and other resources to help you support your patients with mBC who are receiving treatment with HALAVEN. We hope that these resources will help you be the intervention that your patients need and be a champion for your patients’ success. Eisai is committed to helping you give your patients optimal care, and we thank you for all that you do each day.

 

Hear from peers

These roundtable discussions feature insights from nurses who are dedicated to championing their patients' success. Each video highlights information about HALAVEN to help you to be the intervention on your patients' treatment journey. The discussions are moderated by Dr. Jody Pelusi, PhD, FNP, AOCNP, Advanced Oncology Certified Nurse Practitioner at Northern Arizona Hematology & Oncology Associates. Dr. Pelusi is joined by Dr. Kennon McCollum, DNP, FNP-C, APRN-BC, Nurse Practitioner at Georgia Cancer Specialists; Dr. Una Hopkins, DNP, RN, FNP-C, APRN-BC, Administrative Director at Dickstein Cancer Center at White Plains Hospital; Linda Penwarden, RN, MN, AOCN, Oncology Clinical Nurse Specialist at St. Luke's Mountain States Tumor Institute; Amy Schorn, RN, MSN, CNP, Nurse Practitioner at Saint Paul Cancer Center; and Donna Terrill, RN, BSN, OCN, Patient Care Coordinator and Clinical Manager at Summit Healthcare Oncology Services.

Translating Clinical Data to Goals of Therapy for Patients on HALAVEN

Importance of Managing Adverse Reactions in Patients on HALAVEN

Understanding Child-Pugh Score When Starting Patients on HALAVEN

Managing Patients With Neutropenia on HALAVEN: A Patient Case Study

Important Considerations When Starting and Making Dose Modifications for Patients on HALAVEN

Communicating HALAVEN Mechanism of Action to Patients

Importance of Communicating Financial Support Programs to Patients on HALAVEN

Downloadable resources

Download resources or check boxes to add to your Resource Suite ZIP file.

Add all

Brochure about HALAVEN for Nurses Download
HALAVEN Nurse Brochure

Key information about HALAVEN for nurses.

Download now (in English)

Download now (in Spanish)

Add to suite
(in English)
Add to suite
(in Spanish)
HALAVEN Pocket Dosing Guide Download
HALAVEN Pocket Dosing Guide

Information about recommended dosing and dose adjustments.

Download now (in English)

Download now (in Spanish)

Add to suite
(in English)
Add to suite
(in Spanish)
Grading Select Adverse Reactions Flashcard for HALAVEN Download
Adverse Reaction Grading Flashcard

Information about grading select adverse reactions.

Download now
Add to suite
Important Information about HALAVEN and Metastatic Breast Cancer for your HALAVEN Patients
HALAVEN Patient Brochure

Important information about HALAVEN for your patients.

Download now (in English)

Download now (in Spanish)

Add to suite
(in English)
Add to suite
(in Spanish)
Full Prescribing Information for HALAVEN Download
HALAVEN Full Prescribing Information (PI)

A PDF of the full PI.

Download now (in English)

Download now (in Spanish)

Add to suite
(in English)
Add to suite
(in Spanish)

For question about HALAVEN, e-mail Eisai Medical Information at medinfo@eisai.com or call 1.888.274.2378

*Subject to patient eligibility.

Indications

Metastatic Breast Cancer

HALAVEN (eribulin mesylate) Injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Liposarcoma

HALAVEN is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Important Safety Information

Warnings and Precautions

Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.

Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.

Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Adverse Reactions

In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).

In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (≥25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each).

Use in Specific Populations

Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.

Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.